Stockreport

Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

Nuvectis Pharma, Inc.  (NVCT) 
PDF NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histological [Read more]